CJC-1295 (no DAC) + Ipamorelin vs Tesamorelin
CJC-1295 (no DAC) + Ipamorelin is not FDA-approved and rated 3/5 for evidence; Tesamorelin is FDA-approved and rated 5/5. Tesamorelin has more human evidence behind it. Both are banned in sport by WADA. Both are used for growth hormone axis goals.
| Compare |  CJC-1295 (no DAC) + IpamorelinThe classic GH-stimulating pair in one vial. |  TesamorelinThe only FDA-approved GHRH analog — proven against belly fat. |
|---|---|---|
| Category | Growth Hormone Axis | Growth Hormone Axis |
| Evidence | 3/5Each component studied in humans for GH release; the combined long-term outcomes data is thin. | 5/5Phase 3 RCTs in HIV lipodystrophy led to FDA approval; off-label populations less studied. |
| FDA status | Not FDA-approved | FDA-approved (Egrifta, 2010) |
| WADA (sport) | Banned | Banned |
| Also known as | Modified GRF 1-29 + Ipamorelin, CJC/Ipa blend | Egrifta, TH9507 |
| How it works | Two receptors, one pulse: GHRH-receptor stimulation (CJC-1295) plus ghrelin-receptor stimulation (ipamorelin) produces a larger-than-either GH release. Short half-life keeps the pulsatile pattern. | Stimulates pituitary GH release through the GHRH receptor, raising IGF-1 and reducing visceral adipose tissue while preserving the natural pulse pattern. |
| Half-life | CJC no-DAC ≈ 30 min; ipamorelin ≈ 2 h | About 25–40 minutes |
| Commonly reported doses |
|
|
| Route | Subcutaneous | Subcutaneous, abdomen |
| Good once mixed | ~21 days in the fridge | ~14 days in the fridge |
| Top side effects |
|
|
| Lowest price per mg | $3.60 (10 mg vial, 40% off) | $4.20 (10 mg vial, 40% off) |
| Latest lab purity | 99.50% (lot CIP0002) | 99.61% (lot TES0003) |
Want a third? Add another peptide. Doses are commonly reported ranges, not recommendations.